Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death.

Kulkarni PM, Robinson EJ, Sarin Pradhan J, Gartrell-Corrado RD, Rohr BR, Trager MH, Geskin LJ, Kluger HM, Wong PF, Acs B, Rizk EM, Yang C, Mondal M, Moore MR, Osman I, Phelps R, Horst BA, Chen ZS, Ferringer T, Rimm DL, Wang J, Saenger YM.

Clin Cancer Res. 2019 Oct 21. pii: clincanres.1495.2019. doi: 10.1158/1078-0432.CCR-19-1495. [Epub ahead of print]

PMID:
31636101
2.

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD, Wong W, Saenger YM.

Am J Clin Dermatol. 2019 Oct 10. doi: 10.1007/s40257-019-00475-1. [Epub ahead of print]

PMID:
31602560
3.

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

PMID:
30996326
4.

Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.

Rizk EM, Gartrell RD, Barker LW, Esancy CL, Finkel GG, Bordbar DD, Saenger YM.

Hematol Oncol Clin North Am. 2019 Apr;33(2):291-299. doi: 10.1016/j.hoc.2018.12.005. Epub 2019 Jan 17. Review.

PMID:
30833001
5.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in: Nat Med. 2019 Apr 17;:.

6.

Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Gartrell RD, Marks DK, Rizk EM, Bogardus M, GĂ©rard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst BA, Saenger YM.

Clin Cancer Res. 2019 Apr 15;25(8):2494-2502. doi: 10.1158/1078-0432.CCR-18-2847. Epub 2019 Jan 15.

PMID:
30647081
7.

Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG.

J Immunother Cancer. 2019 Jan 15;7(1):10. doi: 10.1186/s40425-018-0485-9.

8.

Correction to: The Role of Oncolytic Viruses in the Treatment of Melanoma.

Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C, Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM.

Curr Oncol Rep. 2018 Nov 13;20(12):100. doi: 10.1007/s11912-018-0749-z.

PMID:
30426304
9.

The Role of Oncolytic Viruses in the Treatment of Melanoma.

Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C, Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM.

Curr Oncol Rep. 2018 Aug 25;20(10):80. doi: 10.1007/s11912-018-0729-3. Review. Erratum in: Curr Oncol Rep. 2018 Nov 13;20(12):100.

10.

IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy.

Chen JC, Perez-Lorenzo R, Saenger YM, Drake CG, Christiano AM.

Cell Syst. 2018 Jul 25;7(1):92-103.e4. doi: 10.1016/j.cels.2018.05.020. Epub 2018 Jun 27.

11.

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.

Blake Z, Marks DK, Gartrell RD, Hart T, Horton P, Cheng SK, Taback B, Horst BA, Saenger YM.

J Immunother Cancer. 2018 Apr 6;6(1):25. doi: 10.1186/s40425-018-0338-6.

12.

Quantitative Analysis of Immune Infiltrates in Primary Melanoma.

Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM.

Cancer Immunol Res. 2018 Apr;6(4):481-493. doi: 10.1158/2326-6066.CIR-17-0360. Epub 2018 Feb 21.

13.

Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform.

Wu CC, Chaudhary KR, Na YH, Welch D, Black PJ, Sonabend AM, Canoll P, Saenger YM, Wang TJC, Wuu CS, Hei TK, Cheng SK.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):191-201. doi: 10.1016/j.ijrobp.2017.05.016. Epub 2017 May 19.

14.

Current and Emerging Therapies in Metastatic Pancreatic Cancer.

Manji GA, Olive KP, Saenger YM, Oberstein P.

Clin Cancer Res. 2017 Apr 1;23(7):1670-1678. doi: 10.1158/1078-0432.CCR-16-2319. Review.

15.

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.

Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, Schwartz G, Saenger YM, Gartrell RD.

J Immunother Cancer. 2016 Apr 19;4:20. doi: 10.1186/s40425-016-0123-3. eCollection 2016.

16.

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.

de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjatic S, Remark R, Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA, Birge MB, Phelps RG, Saenger YM.

Cancer Immunol Immunother. 2015 Sep;64(9):1193-203. doi: 10.1007/s00262-015-1726-0. Epub 2015 Jun 16.

17.

Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.

Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM.

J Invest Dermatol. 2014 Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12.

18.

Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.

Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, Harcharik S, Chang R, Friedlander P, Saenger YM.

Melanoma Res. 2013 Feb;23(1):47-54. doi: 10.1097/CMR.0b013e32835c7e68.

PMID:
23262440
19.

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD.

Cancer Res. 2008 Dec 1;68(23):9884-91. doi: 10.1158/0008-5472.CAN-08-2233.

20.
21.

Current topics in melanoma.

Wolchok JD, Saenger YM.

Curr Opin Oncol. 2007 Mar;19(2):116-20. Review.

PMID:
17272983
22.

Cytokines in cytotherapy.

Saenger Y, Wolchok J.

Cytotherapy. 2006;8(4):313-4. No abstract available.

PMID:
16923605

Supplemental Content

Loading ...
Support Center